AntiCancer, Inc; San Diego, CA USA; Department of Surgery; University of California San Diego; San Diego, CA USA; Yokohama City University Graduate School of Medicine; Yokohama, Japan.
Cell Cycle. 2013 Sep 1;12(17):2774-80. doi: 10.4161/cc.25872. Epub 2013 Aug 6.
The XPA1 human pancreatic cancer cell line is dimorphic, with spindle stem-like cells and round non-stem cells. We report here the in vitro IC 50 values of stem-like and non-stem XPA1 human pancreatic cells cells for: (1) 5-fluorouracil (5-FU), (2) cisplatinum (CDDP), (3) gemcitabine (GEM), and (4) tumor-targeting Salmonella typhimurium A1-R (A1-R). IC 50 values of stem-like XPA1 cells were significantly higher than those of non-stem XPA1 cells for 5-FU (P = 0.007) and CDDP (P = 0.012). In contrast, there was no difference between the efficacy of A1-R on stem-like and non-stem XPA1 cells. In vivo, 5-FU and A1-R significantly reduced the tumor weight of non-stem XPA1 cells (5-FU; P = 0.028; A1-R; P = 0.011). In contrast, only A1-R significantly reduced tumor weight of stem-like XPA1 cells (P = 0.012). The combination A1-R with 5-FU improved the antitumor efficacy compared with 5-FU monotherapy on the stem-like cells (P = 0.004). The results of the present report indicate A1-R is a promising therapy for chemo-resistant pancreatic cancer stem-like cells.
XPA1 人胰腺癌细胞系呈二态性，具有梭形干细胞样细胞和圆形非干细胞样细胞。我们在此报告干细胞样和非干细胞样 XPA1 人胰腺癌细胞对以下物质的体外半数抑制浓度 (IC50) 值：(1) 5-氟尿嘧啶 (5-FU)、(2) 顺铂 (CDDP)、(3) 吉西他滨 (GEM) 和 (4) 靶向肿瘤的鼠伤寒沙门氏菌 A1-R (A1-R)。与非干细胞样 XPA1 细胞相比，干细胞样 XPA1 细胞对 5-FU (P = 0.007) 和 CDDP (P = 0.012) 的 IC50 值明显更高。相比之下，A1-R 对干细胞样和非干细胞样 XPA1 细胞的疗效没有差异。在体内，5-FU 和 A1-R 显著降低了非干细胞样 XPA1 细胞的肿瘤重量 (5-FU；P = 0.028；A1-R；P = 0.011)。相比之下，只有 A1-R 显著降低了干细胞样 XPA1 细胞的肿瘤重量 (P = 0.012)。与 5-FU 单药治疗相比，A1-R 联合 5-FU 可提高对干细胞样细胞的抗肿瘤疗效 (P = 0.004)。本报告的结果表明，A1-R 是一种有前途的化疗耐药胰腺癌细胞干样治疗方法。
